Antiviral Drugs Market By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, Integrase Inhibitors, Entry Inhibitors, Fusion Inhibitors, Others), By Virus Type (HIV, Hepatitis B and C, Influenza, Herpes Simplex Virus, Respiratory Syncytial Virus, Others), By Therapeutic Application (Prophylactic, Curative, Symptomatic Treatment, Others), By Route of Administration (Oral, Injectable, Topical, Intranasal), By End-User (Hospitals, Clinics, Home Care Settings, Research Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Antiviral Drugs Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising viral infections increase demand for antiviral medications globally.

3.2.2. Preventive healthcare awareness boosts demand for antiviral drugs.

3.2.3. Aging population is more susceptible to viral infections, necessitating treatment.

3.3. Key industry pitfalls & challenges

3.3.1. High R&D costs limit new antiviral drugs entering market.

3.3.2. Side effects and resistance can limit antiviral drug efficacy.

3.3.3. Intense competition from generics restricts profitability in market.

3.4. Market Opportunities

3.4.1. Emerging markets present significant growth opportunities for antivirals.

3.4.2. Combination therapies enhance treatment effectiveness and market potential.

3.4.3. Digital health technologies improve patient adherence and monitoring effectiveness.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Antiviral Drugs Market, Drug Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Protease Inhibitors (PIs)

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Integrase Inhibitors

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Entry Inhibitors

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Fusion Inhibitors

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.8. Others

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Antiviral Drugs Market, Virus Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Virus Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. HIV

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Hepatitis B and C

5.3.1. Market Size and Forecast, 2025-2035(USD Billion)

5.4. Influenza

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Herpes Simplex Virus (HSV)

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Respiratory Syncytial Virus (RSV)

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Others

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Antiviral Drugs Market, Therapeutic Application Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Therapeutic Application, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Prophylactic

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Curative

6.3.1. Market Size and Forecast, 2025-2035(USD Billion)

6.4. Symptomatic Treatment

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Others

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Antiviral Drugs Market, Route of Administration Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Oral

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Injectable

7.3.1. Market Size and Forecast, 2025-2035(USD Billion)

7.4. Topical

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Intranasal

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Antiviral Drugs Market, End-User Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-User, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Clinics

8.3.1. Market Size and Forecast, 2025-2035(USD Billion)

8.4. Home Care Settings

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Research Institutions

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Antiviral Drugs Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Drug Type, 2025-2035

9.2.3. North America Market Revenue, By Virus Type, 2025-2035

9.2.4. North America Market Revenue, By Therapeutic Application, 2025-2035

9.2.5. North America Market Revenue, By Route of Administration, 2025-2035

9.2.6. North America Market Revenue, By End-User, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Drug Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Virus Type, 2025-2035

9.2.7.3. U.S. Market Revenue, By Therapeutic Application, 2025-2035

9.2.7.4. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-User, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Drug Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Virus Type, 2025-2035

9.2.8.3. Canada Market Revenue, By Therapeutic Application, 2025-2035

9.2.8.4. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.5. Canada Market Revenue, By End-User, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Drug Type, 2025-2035

9.3.3. Europe Market Revenue, By Virus Type, 2025-2035

9.3.4. Europe Market Revenue, By Therapeutic Application, 2025-2035

9.3.5. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.6. Europe Market Revenue, By End-User, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Drug Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Virus Type, 2025-2035

9.3.7.3. Germany Market Revenue, By Therapeutic Application, 2025-2035

9.3.7.4. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.5. Germany Market Revenue, By End-User, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Drug Type, 2025-2035

9.3.8.2. France Market Revenue, By Virus Type, 2025-2035

9.3.8.3. France Market Revenue, By Therapeutic Application, 2025-2035

9.3.8.4. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.5. France Market Revenue, By End-User, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Drug Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Virus Type, 2025-2035

9.3.9.3. U.K. Market Revenue, By Therapeutic Application, 2025-2035

9.3.9.4. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-User, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Drug Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Virus Type, 2025-2035

9.3.10.3. Italy Market Revenue, By Therapeutic Application, 2025-2035

9.3.10.4. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.5. Italy Market Revenue, By End-User, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Drug Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Virus Type, 2025-2035

9.3.11.3. Spain Market Revenue, By Therapeutic Application, 2025-2035

9.3.11.4. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.5. Spain Market Revenue, By End-User, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Drug Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Virus Type, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Therapeutic Application, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-User, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Virus Type, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Therapeutic Application, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-User, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Drug Type, 2025-2035

9.4.7.2. China Market Revenue, By Virus Type, 2025-2035

9.4.7.3. China Market Revenue, By Therapeutic Application, 2025-2035

9.4.7.4. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.5. China Market Revenue, By End-User, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Drug Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Virus Type, 2025-2035

9.4.8.3. Japan Market Revenue, By Therapeutic Application, 2025-2035

9.4.8.4. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.5. Japan Market Revenue, By End-User, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Drug Type, 2025-2035

9.4.9.2. India Market Revenue, By Virus Type, 2025-2035

9.4.9.3. India Market Revenue, By Therapeutic Application, 2025-2035

9.4.9.4. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.5. India Market Revenue, By End-User, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Drug Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Virus Type, 2025-2035

9.4.10.3. Australia Market Revenue, By Therapeutic Application, 2025-2035

9.4.10.4. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.5. Australia Market Revenue, By End-User, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Drug Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Virus Type, 2025-2035

9.4.11.3. South Korea Market Revenue, By Therapeutic Application, 2025-2035

9.4.11.4. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-User, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Drug Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Virus Type, 2025-2035

9.4.12.3. Singapore Market Revenue, By Therapeutic Application, 2025-2035

9.4.12.4. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-User, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Virus Type, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Therapeutic Application, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Drug Type, 2025-2035

9.5.3. Latin America Market Revenue, By Virus Type, 2025-2035

9.5.4. Latin America Market Revenue, By Therapeutic Application, 2025-2035

9.5.5. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.6. Latin America Market Revenue, By End-User, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Drug Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Virus Type, 2025-2035

9.5.7.3. Brazil Market Revenue, By Therapeutic Application, 2025-2035

9.5.7.4. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-User, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Drug Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Virus Type, 2025-2035

9.5.8.3. Argentina Market Revenue, By Therapeutic Application, 2025-2035

9.5.8.4. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-User, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Drug Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Virus Type, 2025-2035

9.5.9.3. Mexico Market Revenue, By Therapeutic Application, 2025-2035

9.5.9.4. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-User, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Drug Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Virus Type, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Therapeutic Application, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-User, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Drug Type, 2025-2035

9.6.3. MEA Market Revenue, By Virus Type, 2025-2035

9.6.4. MEA Market Revenue, By Therapeutic Application, 2025-2035

9.6.5. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.6. MEA Market Revenue, By End-User, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Drug Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Virus Type, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Therapeutic Application, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-User, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Drug Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Virus Type, 2025-2035

9.6.8.3. South Africa Market Revenue, By Therapeutic Application, 2025-2035

9.6.8.4. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-User, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Drug Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Virus Type, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Therapeutic Application, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

10. Company Profile

10.1. Gilead Sciences, Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. GlaxoSmithKline

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. AbbVie Inc.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Merck & Co., Inc.

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Bristol-Myers Squibb

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Johnson & Johnson

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. AstraZeneca

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Roche Holding AG

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Novartis AG

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Sofinnova Partners

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Horizon Therapeutics

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. ViiV Healthcare

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Eisai Co., Ltd.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Aicuris Anti-infective Cure

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Kissei Pharmaceutical Co., Ltd.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis